Company / Operating Cash Flow per Share
UroGen Pharma Ltd. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.85
FY2025
5-year range
-$3.85 / -$2.35
FY2021-FY2025
Trend
-63.6%
vs FY2024
Sector context
#186 of 212
Health Care
What the data says
UroGen Pharma Ltd.'s operating cash flow per share of $-3.85 is lower than 88% of companies in the Health Care sector (FY2025). Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-3.85 in FY2025 to $1.82 in FY2016.
Based on SEC 10-K filings.
-3.85 in FY2025.
Remained stable around $-3.85 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 212This company -$3.85 Sector average -$14.72
▼
+73.9% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 63.6% year-over-year.
- Ranks #186 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.85 | -63.6% |
| FY2024 | -$2.35 | +37.9% |
| FY2023 | -$3.79 | -0.2% |
| FY2022 | -$3.78 | +1.3% |
| FY2021 | -$3.83 | -13.4% |
| FY2020 | -$3.38 | -472.4% |
| FY2019 | -$0.59 | +78.3% |
| FY2018 | -$2.71 | -175.7% |
| FY2017 | -$0.98 | -154.2% |
| FY2016 | $1.82 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026